Sarepta Therapeutics (SRPT) stock faces downgrades as it suspends 2025 revenue guidance amid safety concerns for its Duchenne gene therapy. Read more here.

In May, Sarepta’s stock dropped further after it lowered its 2025 revenue guidance from $2.9 billion - $3.1 billion to $2.3 billion - $2.6 billion. This was attributed to ELEVIDYS.

Sarepta stock tanked Friday after a new patient death was uncovered, spurring an FDA request to halt shipments of an ...

Analysts have recently evaluated Sarepta Therapeutics and provided 12-month price targets. The average target is $102.54, accompanied by a high estimate of $202.00 and a low estimate of $40.00. A ...

On June 18, TD Cowen downgraded Sarepta Therapeutics, Inc. (NASDAQ:SRPT)’s stock to “Hold” from “Buy,” reducing the price objective to $24 from the prior target of $62, as reported by ...

Shares of Sarepta Therapeutics closed down as much as 42% to hit a nine-year low of $18.30 on Monday after a second death of a male teenage patient who had received its gene therapy, Elevidys ...

What Happened? A number of healthcare stocks fell in the afternoon session after several negative developments weighed on the ...

A second Duchenne patient being treated with Sarepta's gene therapy has died, sending the biotech's stock plummeting. Thursday, July 31, 2025 Biotech's Future - Innovation, AI and our Competitive Edge ...

Sarepta Therapeutics shares sank to their lowest level in nine years Monday after a second patient taking its Elevidys drug died. The patient was being treated for Duchenne muscular dystrophy, and ...

NEW YORK, June 26, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into Sarepta Therapeutics, Inc. (NASDAQ: SRPT) for potential ...